Stacy Lewandowski
Medical · Beatrice, NENPI 1376639120
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 35.6% of the total. 2025 is the largest year on record at $786, 9.9 times the $79 reported in 2021.
Across 80 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$515
- Novartis$139
- Pfizer$121
- Amgen$117
- Novo Nordisk$108
- Astellas Pharma US Inc$65
- plus $382 from 17 others
What the payments were for
- Food & beverage$1,447100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $515 |
| Novartis | 8 | $139 |
| Pfizer | 7 | $121 |
| Amgen | 8 | $117 |
| Novo Nordisk | 7 | $108 |
| Astellas Pharma US Inc | 2 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Boehringer Ingelheim | 2 | $31 |
| AstraZeneca | 2 | $30 |
| Lilly USA, LLC | 2 | $26 |
| Biogen | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Organon | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Zealand Pharma US, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$1,447 in reported general payments places this provider in the 75th percentile of 216 medical providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $47,449 |
| MounjaroTirzepatide | 39 | $44,183 |
| JardianceEmpagliflozin | 38 | $28,643 |
| JanuviaSitagliptin Phosphate | 21 | $21,499 |
| FarxigaDapagliflozin Propanediol | 27 | $20,937 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $18,331 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $11,318 |
| ProtonixPantoprazole Sodium | 11 | $9,872 |
| XareltoRivaroxaban | 12 | $7,893 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,699 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,337 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 13 | $4,791 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $3,929 |
| Ventolin HfaAlbuterol Sulfate | 45 | $3,392 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $108 | $47,44937 claims |
| Lilly USA, LLCMounjaro | $26 | $44,18339 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $31 | $34,98051 claims |
| MerckJanuvia | $16 | $21,49921 claims |
| AstraZenecaFarxiga | $30 | $20,93727 claims |
| PfizerProtonix | $121 | $9,87211 claims |
| Johnson & JohnsonXarelto | $21 | $7,89312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 216 medical providers in Nebraska.
Other medical in Beatrice
- Erin DornBeatrice$2K
- Michelle SitzmanLincoln$206K
- Kaitlin MatthesLincoln$98K
- Kelly HooverOmaha$16K
- Lyndsey DegenhardtElkhorn$12K
- Jacob RidderOmaha$12K
- Angelika StevensOmaha$8K
- Jennelea MontanezOmaha$8K
- Shannon BusterPapillion$8K
- Jay ArthurLincoln$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.